Juliet Tammenoms Bakker, 10% Owner at Aimmune Therapeutics, Inc. (AIMT), bought 9,375 shares at $32.00 ($300K) on 2018-02-22, disclosed to the SEC on 2018-02-26.
Open-market purchase of $300k AIMT by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| RXST | BUY | 2024-02-15 | $407K | — | Filing → |
| RXST | SELL | 2023-11-30 | $29.4M | — | Filing → |
| RXST | SELL | 2023-11-16 | $13.6M | — | Filing → |